Founded in 2015 and headquartered in Atglen, Pennsylvania, Incintas Therapeutics collaborates with scientists, physicians, and business professionals to create effective treatments for infertility and in-vitro fertilization. By utilizing genomic data, the company aims to determine the most optimal times for pregnancy and successful in-vitro fertilization, while also expanding the fertility window. Their novel therapeutic has the potential to significantly increase fertility success rates in assisted reproductive technologies, such as in-vitro fertilization, benefiting the 15% of the global population who suffer from infertility. With the goal of improving embryo implantation and pregnancy outcomes, Incintas Therapeutics focuses on enhancing bioavailability in the uterus. This breakthrough technology presents a promising investment opportunity in the field of women's health.